Financial Performance - Sanara MedTech Inc. reported a quarterly loss of $0.41 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.31, and compared to a loss of $0.21 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $23.43 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.32%, and showing an increase from year-ago revenues of $18.54 million [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $25.35 million, and for the current fiscal year, it is -$1.78 on revenues of $107.2 million [7] - The estimate revisions trend for Sanara MedTech is mixed, leading to a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Market Performance - Sanara MedTech shares have increased by approximately 5.7% since the beginning of the year, outperforming the S&P 500, which gained only 0.1% [3] - The outlook for the industry, specifically the Medical - Products sector, is currently in the bottom 31% of over 250 Zacks industries, which may impact the stock's performance [8]

Group 1: Earnings Performance - Verve Therapeutics reported a quarterly loss of $0.35 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.71, representing an earnings surprise of 50.70% [1] - The company has surpassed consensus EPS estimates in all four of the last quarters [2] - The revenue for the quarter ended March 2025 was $32.98 million, exceeding the Zacks Consensus Estimate by 362.76%, compared to $5.7 million in the same quarter last year [2] Group 2: Stock Performance and Outlook - Verve Therapeutics shares have declined approximately 26.2% since the beginning of the year, while the S&P 500 has gained 0.1% [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.70 on revenues of $8.29 million, and for the current fiscal year at -$2.73 on revenues of $29.74 million [7] - The Zacks Rank for Verve Therapeutics is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Drugs industry, to which Verve Therapeutics belongs, is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Plus Therapeutics, is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year change of +77.3% [9]

分组1 - Kamada reported quarterly earnings of $0.07 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.04 per share a year ago [1] - The company posted revenues of $44.02 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 5.28%, compared to $37.74 million in the same quarter last year [2] - Kamada shares have increased approximately 13.1% since the beginning of the year, outperforming the S&P 500's gain of 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $44.55 million, and for the current fiscal year, it is $0.27 on revenues of $179.87 million [7] - The Medical - Biomedical and Genetics industry, to which Kamada belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8]

Company Performance - European Wax Center, Inc. (EWCZ) reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, and up from $0.13 per share a year ago, representing an earnings surprise of 340% [1] - The company posted revenues of $51.43 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.11%, although this is a slight decrease from year-ago revenues of $51.87 million [2] - Over the last four quarters, the company has consistently surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Outlook - European Wax Center shares have declined approximately 40.6% since the beginning of the year, contrasting with the S&P 500's gain of 0.1% [3] - The company's earnings outlook is favorable, with a current consensus EPS estimate of $0.12 on revenues of $57.77 million for the coming quarter, and $0.31 on revenues of $211.81 million for the current fiscal year [7] - The estimate revisions trend for European Wax Center is currently favorable, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Cosmetics industry, to which European Wax Center belongs, is currently ranked in the bottom 24% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of European Wax Center may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Actelis Networks, Inc. reported a quarterly loss of $0.22 per share, which was better than the Zacks Consensus Estimate of a loss of $0.25, and an improvement from a loss of $0.50 per share a year ago, representing an earnings surprise of 12% [1] - The company posted revenues of $0.72 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 39.92%, and a slight decrease from year-ago revenues of $0.73 million [2] - Actelis Networks has not surpassed consensus revenue estimates over the last four quarters [2] Stock Performance - Actelis Networks shares have declined approximately 42.5% since the beginning of the year, contrasting with the S&P 500's decline of only 0.6% [3] - The current Zacks Rank for Actelis Networks is 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $3 million, and for the current fiscal year, it is -$0.42 on revenues of $10 million [7] - The estimate revisions trend for Actelis Networks is currently unfavorable, which may impact future stock movements [6] Industry Context - The Communication - Components industry, to which Actelis Networks belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting a challenging environment for the stock [8]

Financial Performance - Inovio Pharmaceuticals reported a quarterly loss of $0.51 per share, better than the Zacks Consensus Estimate of a loss of $0.74, and an improvement from a loss of $1.31 per share a year ago, representing an earnings surprise of 31.08% [1] - The company posted revenues of $0.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 30%, compared to zero revenues a year ago [2] Stock Performance - Inovio shares have increased by approximately 6% since the beginning of the year, while the S&P 500 has declined by 0.6% [3] - The current Zacks Rank for Inovio is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.60 on revenues of $0.05 million, and for the current fiscal year, it is -$2.27 on revenues of $7.7 million [7] - The Medical - Biomedical and Genetics industry, to which Inovio belongs, is currently in the top 35% of Zacks industries, suggesting a favorable outlook for stocks within this sector [8]

Company Performance - MacroGenics reported a quarterly loss of $0.65 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.61, and an improvement from a loss of $0.84 per share a year ago, indicating a surprise of -6.56% [1] - The company posted revenues of $13.19 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 5.45%, but showing an increase from $9.1 million in the same quarter last year [2] - Over the last four quarters, MacroGenics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - MacroGenics shares have declined approximately 51.1% since the beginning of the year, contrasting with the S&P 500's decline of -0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $18.13 million, and for the current fiscal year, it is -$2.21 on revenues of $78.51 million [7] Industry Outlook - The Medical - Products industry, to which MacroGenics belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The earnings outlook for MacroGenics is favorable, with a Zacks Rank of 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Core Viewpoint - Dare Bioscience, Inc. reported a quarterly loss of $0.50 per share, which was better than the Zacks Consensus Estimate of a loss of $0.63, indicating an earnings surprise of 20.63% [1] Financial Performance - The company posted revenues of $0.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 95.83%, compared to revenues of $0.01 million a year ago [2] - Over the last four quarters, the company has surpassed consensus EPS estimates four times but has not been able to beat consensus revenue estimates [2] Stock Performance - Dare Bioscience shares have lost about 7.7% since the beginning of the year, while the S&P 500 has declined by 0.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.43 on $0.6 million in revenues, and for the current fiscal year, it is -$1.97 on $3.3 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Dare Bioscience belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - Spero Therapeutics reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.55, representing an earnings surprise of 54.55% [1] - The company posted revenues of $5.87 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 46.60%, compared to revenues of $9.27 million a year ago [2] - Over the last four quarters, Spero Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Spero Therapeutics shares have declined approximately 40.8% since the beginning of the year, while the S&P 500 has only declined by 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.32 on $11 million in revenues, and for the current fiscal year, it is -$2.32 on $60 million in revenues [7] - The estimate revisions trend for Spero Therapeutics is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Spero Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Spero Therapeutics' stock performance [5]

Treace Medical Concepts (TMCI) closed the last trading session at $7.20, gaining 6.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.16 indicates a 41.1% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $2.16. While the lowest estimate of $8 indicates an 11.1% increase from the current price level, the most optimistic ana ...